Also, we won't really conquer covid until everyone has built up immunity and the countries with the lowest vaccination rates are the ones that can't afford this kind of markup.

This is still a problem that affects us all. Not saying that it would be less bad if it didn't affect us, but I mean that a hard-fought vaccine for a niche illness could have to be expensive to amortize development costs. Covid is not that.

Ps and like @Beltalowda says a lot of their R&D was publicly funded. And they got a huge boost by bringing their thus far experimental RNA vaccine tech into the mainstream.